Janux Therapeutics (JANX) Common Equity (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Common Equity data on file, last reported at $941.5 million in Q1 2026.

• On a quarterly basis, Common Equity fell 7.01% year-over-year to $941.5 million in Q1 2026; TTM through Mar 2026 was $941.5 million, a 7.01% decrease from a year earlier, with the FY2025 full-year figure at $956.8 million, down 6.45% from the prior year.
• Common Equity for Q1 2026 stood at $941.5 million, down from $956.8 million in the prior quarter.
• Over the last five years, Common Equity for JANX reached as high as $1.0 billion in Q4 2024 and fell as low as $299.5 million in Q2 2023.
• Historically, Common Equity has averaged $619.2 million across 5 years, with a median of $655.8 million in 2024.
• Across the five-year window, Common Equity jumped 2223.2% in 2022 and retreated 12.9% in 2023, its largest moves.
• Year by year, Common Equity stood at $320.7 million in 2022, then advanced by 7.36% to $344.3 million in 2023, then surged by 197.02% to $1.0 billion in 2024, then fell by 6.45% to $956.8 million in 2025, then retreated by 1.6% to $941.5 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $941.5 million in Q1 2026, $956.8 million in Q4 2025, and $976.6 million in Q3 2025.